The US FTC announces its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals

On April 4, 2006, the FTC published notice of its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals. See 71 Fed. Reg. 16,779 (April 4, 2006). The initial stage of the study would involve detailed information requests, akin to subpoenas, to as many as 80 brand-name pharmaceutical manufacturers — probably including any brand-name pharmaceutical manufacturer that has faced or soon will face generic competition — and an even larger number of generic manufacturers. All pharmaceutical companies should be aware of the following issues: The FTC Study as proposed will cover a wide-range of pharmaceutical products that have faced generic competition since January 1, 1999, and is not limited only to products for which an authorized generic was

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)

Quotation

Michael Labson, Geoffrey Hobart, Eric Holder, Mark Lynch, Richard Kingham, Peter Safir, Theodore Voorhees Jr, James R. Dean, David W. Addis, Ethan M. Posner, The US FTC announces its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals, 4 April 2006, e-Competitions April 2006, Art. N° 95930

Visites 20

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues